United States Biotechnology & Medical Research

Shire Viropharma Inc (VPHM)

Track

Ticker: VPHM Exchange: NSQ
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Planned sale 24 Dec 2012
Value US$1,167,020.01 | Price 107.42 | Shares 17,173 (+36.3%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2012-12-27 2012-12-24 PlS Planned sale Broom Colin MD

VP & Chief Scientific Officer

Officer
17,173 +36.3%
107.42
US$1,167,020 		17,173 +36.3% 107.42 US$1,167,020
2012-12-17 2012-12-13 S Sale BROOKE PAUL A Non-Executive Director
83,706 +48.4%
40.82
US$4,409,792 		83,706 +48.4% 40.82 US$4,409,792
2012-12-12 2012-12-10 PlS Planned sale Broom Colin MD

VP & Chief Scientific Officer

Officer
56,638 -12.4%
368.19
US$3,170,795 		56,638 -12.4% 368.19 US$3,170,795
2012-12-12 2012-12-10 S Sale Broom Colin MD

VP & Chief Scientific Officer

Officer
50,000 -57.0%
24.07
US$1,203,360 		50,000 -57.0% 24.07 US$1,203,360
2012-12-12 2012-12-10 S Sale Broom Colin MD

VP & Chief Scientific Officer

Officer
10,000 -21.0%
24.07
US$240,672 		10,000 -21.0% 24.07 US$240,672
2012-12-05 2012-12-03 S Sale Wolf John Peter III

VP, General Counsel

Officer
18,000 -100.0%
24.85
US$447,257 		18,000 -100.0% 24.85 US$447,257
2012-12-05 2012-12-03 B Purchase DOUGHERTY MICHAEL R Non-Executive Director
2,500 +55.6%
25.07
US$62,675 		2,500 +55.6% 25.07 US$62,675
2012-12-05 2012-12-03 S Sale CLAYPOOL WILLIAM D MD Non-Executive Director
10,000 -18.3%
24.80
US$248,000 		10,000 -18.3% 24.80 US$248,000
2012-12-04 2012-11-30 S Sale GLASER ROBERT Non-Executive Director
10,000 -19.5%
24.78
US$247,795 		10,000 -19.5% 24.78 US$247,795
2012-12-04 2012-11-30 S Sale GLASER ROBERT Non-Executive Director
20,000 -32.6%
24.78
US$495,590 		20,000 -32.6% 24.78 US$495,590
2012-11-30 2012-11-28 S Sale CLAYPOOL WILLIAM D MD Non-Executive Director
15,000 -21.6%
24.22
US$363,326 		15,000 -21.6% 24.22 US$363,326
2012-11-30 2012-11-28 S Sale CLAYPOOL WILLIAM D MD Non-Executive Director
2,500 -4.4%
24.22
US$60,554 		2,500 -4.4% 24.22 US$60,554
2012-11-15 2012-11-13 S Sale CLAYPOOL WILLIAM D MD Non-Executive Director
12,500 -18.7%
25.01
US$312,585 		12,500 -18.7% 25.01 US$312,585
2012-11-15 2012-11-13 S Sale CLAYPOOL WILLIAM D MD Non-Executive Director
10,000 -15.5%
24.84
US$248,426 		10,000 -15.5% 24.84 US$248,426
2012-11-13 2012-11-08 S Sale MILANO VINCENT

President and CEO

Executive Director
41,418 -30.5%
24.54
US$1,016,522 		41,418 -30.5% 24.54 US$1,016,522
2012-11-13 2012-11-08 S Sale MILANO VINCENT

President and CEO

Executive Director
42,000 -30.8%
24.54
US$1,030,806 		42,000 -30.8% 24.54 US$1,030,806
2012-11-05 2012-11-02 S Sale CLAYPOOL WILLIAM D MD Non-Executive Director
10,000 -15.5%
25.37
US$253,703 		10,000 -15.5% 25.37 US$253,703
2012-06-13 2012-06-11 S Sale CLAYPOOL WILLIAM D MD Non-Executive Director
10,000 -13.4%
20.04
US$200,430 		10,000 -13.4% 20.04 US$200,430
2012-03-27 2012-03-23 PlS Planned sale Pietrusko Robert

VP, Regulatory & Quality

Officer
20,000 -82.9%
30.00
US$600,000 		20,000 -82.9% 30.00 US$600,000
2012-03-12 2012-03-09 S Sale Morris Richard Steven

Chief Accounting Officer

Officer
1,300 -51.1%
29.71
US$38,618 		1,300 -51.1% 29.71 US$38,618
2012-03-12 2012-03-09 S Sale Fletcher Robert C.

V.P., Business Development

Officer
32,000 -99.3%
29.65
US$948,954 		32,000 -99.3% 29.65 US$948,954
2012-03-07 2012-03-05 S Sale Morris Richard Steven

Chief Accounting Officer

Officer
5,300 -81.0%
33.01
US$174,953 		5,300 -81.0% 33.01 US$174,953
2012-03-07 2012-03-05 S Sale DOYLE THOMAS F

VP Strategic Initiatives

Officer
210,000 -80.0%
32.48
US$6,820,212 		210,000 -80.0% 32.48 US$6,820,212
2012-03-06 2012-03-01 S Sale SOLAND DANIEL B

VP, Chief Operating Officer

Officer
30,000 -41.2%
32.99
US$989,700 		30,000 -41.2% 32.99 US$989,700
2012-03-05 2012-03-01 S Sale Rowland Charles A Jr

VP, Chief Financial Officer

Officer
12,750 -42.7%
32.11
US$409,434 		12,750 -42.7% 32.11 US$409,434
2012-03-05 2012-03-01 S Sale Rowland Charles A Jr

VP, Chief Financial Officer

Officer
70,000 -70.1%
32.12
US$2,248,197 		70,000 -70.1% 32.12 US$2,248,197
2011-12-16 2011-12-14 B Purchase Baker Biotech Capital (GP), LLC Large shareholder
50,566 +2.6%
27.29
US$1,379,860 		50,566 +2.6% 27.29 US$1,379,860
2011-12-16 2011-12-14 B Purchase Baker Brothers Life Sciences Capital (GP), LLC Large shareholder
291,706 +3.1%
27.29
US$7,960,161 		291,706 +3.1% 27.29 US$7,960,161
2011-12-16 2011-12-14 B Purchase 14159 capital (GP), LLC Large shareholder
7,828 +2.6%
27.29
US$213,613 		7,828 +2.6% 27.29 US$213,613
2011-12-15 2011-12-14 PlS Planned sale Broom Colin MD

VP & Chief Scientific Officer

Officer
25,000 -56.3%
25.17
US$629,250 		25,000 -56.3% 25.17 US$629,250
2011-12-15 2011-12-14 PlS Planned sale Broom Colin MD

VP & Chief Scientific Officer

Officer
25,000 -56.3%
25.50
US$637,500 		25,000 -56.3% 25.50 US$637,500
2011-12-14 2011-12-13 PlS Planned sale Broom Colin MD

VP & Chief Scientific Officer

Officer
22,330 -53.5%
23.50
US$524,755 		22,330 -53.5% 23.50 US$524,755
2011-12-14 2011-12-12 PlS Planned sale Broom Colin MD

VP & Chief Scientific Officer

Officer
17,670 -47.6%
23.50
US$415,317 		17,670 -47.6% 23.50 US$415,317
2011-12-05 2011-12-01 S Sale DOYLE THOMAS F

VP Strategic Initiatives

Officer
10,000 -16.0%
23.82
US$238,159 		10,000 -16.0% 23.82 US$238,159
2011-12-01 2011-11-30 PlS Planned sale Pietrusko Robert

VP, Regulatory & Quality

Officer
20,000 -83.6%
24.00
US$480,000 		20,000 -83.6% 24.00 US$480,000
2011-11-29 2011-11-28 PlS Planned sale Pietrusko Robert

VP, Regulatory & Quality

Officer
19,000 -82.9%
23.00
US$437,000 		19,000 -82.9% 23.00 US$437,000
2011-11-29 2011-11-28 S Sale GLASER ROBERT Non-Executive Director
5,000 -11.9%
23.00
US$115,000 		5,000 -11.9% 23.00 US$115,000
2011-11-28 2011-11-23 PlS Planned sale Pietrusko Robert

VP, Regulatory & Quality

Officer
1,000 -25.6%
23.00
US$23,000 		1,000 -25.6% 23.00 US$23,000
2011-11-23 2011-11-21 PlS Planned sale MILANO VINCENT

President and CEO

Executive Director
41,691 -35.4%
22.53
US$939,127 		41,691 -35.4% 22.53 US$939,127
2011-11-23 2011-11-21 PlS Planned sale MILANO VINCENT

President and CEO

Executive Director
19,996 -20.8%
22.53
US$450,428 		19,996 -20.8% 22.53 US$450,428
2011-11-23 2011-11-21 PlS Planned sale MILANO VINCENT

President and CEO

Executive Director
15,000 -16.4%
22.53
US$337,888 		15,000 -16.4% 22.53 US$337,888
2011-11-17 2011-11-16 S Sale Morris Richard Steven

Chief Accounting Officer

Officer
2,000 -63.2%
22.59
US$45,181 		2,000 -63.2% 22.59 US$45,181
2011-11-15 2011-11-14 PlS Planned sale Pietrusko Robert

VP, Regulatory & Quality

Officer
20,000 -83.6%
22.00
US$440,000 		20,000 -83.6% 22.00 US$440,000
2011-11-09 2011-11-07 S Sale Wolf John Peter III

VP, General Counsel

Officer
12,250 -100.0%
21.08
US$258,194 		12,250 -100.0% 21.08 US$258,194
2011-11-08 2011-11-07 S Sale Broom Colin MD

VP & Chief Scientific Officer

Officer
200 -1.0%
21.01
US$4,202 		200 -1.0% 21.01 US$4,202
2011-11-08 2011-11-07 S Sale Broom Colin MD

VP & Chief Scientific Officer

Officer
19,800 -50.2%
21.00
US$415,800 		19,800 -50.2% 21.00 US$415,800
2011-11-02 2011-11-01 PlS Planned sale Broom Colin MD

VP & Chief Scientific Officer

Officer
24,121 -55.4%
20.05
US$483,641 		24,121 -55.4% 20.05 US$483,641
2011-11-02 2011-10-31 S Sale Broom Colin MD

VP & Chief Scientific Officer

Officer
20,495 -51.3%
20.42
US$418,555 		20,495 -51.3% 20.42 US$418,555
2011-10-06 2011-10-05 B Purchase Baker Brothers Life Sciences Capital (GP), LLC Large shareholder
145,763 +1.6%
18.18
US$2,650,423 		145,763 +1.6% 18.18 US$2,650,423
2011-10-06 2011-10-05 B Purchase Baker Biotech Capital (GP), LLC Large shareholder
16,278 +0.9%
18.18
US$295,985 		16,278 +0.9% 18.18 US$295,985
2011-10-06 2011-10-05 B Purchase 14159 capital (GP), LLC Large shareholder
6,017 +2.1%
18.18
US$109,408 		6,017 +2.1% 18.18 US$109,408
2011-10-06 2011-10-04 B Purchase Baker Brothers Life Sciences Capital (GP), LLC Large shareholder
45,584 +0.5%
17.48
US$796,644 		45,584 +0.5% 17.48 US$796,644
2011-10-06 2011-10-04 B Purchase Baker Biotech Capital (GP), LLC Large shareholder
2,511 +0.1%
17.48
US$43,883 		2,511 +0.1% 17.48 US$43,883
2011-10-06 2011-10-04 B Purchase 14159 capital (GP), LLC Large shareholder
1,905 +0.7%
17.48
US$33,293 		1,905 +0.7% 17.48 US$33,293
2011-10-03 2011-10-03 B Purchase Baker Brothers Life Sciences Capital (GP), LLC Large shareholder
445,574 +5.0%
17.71
US$7,890,269 		445,574 +5.0% 17.71 US$7,890,269
2011-10-03 2011-10-03 B Purchase Baker Brothers Life Sciences Capital (GP), LLC Large shareholder
70,629 +0.8%
17.62
US$1,244,589 		70,629 +0.8% 17.62 US$1,244,589
2011-10-03 2011-09-30 B Purchase Baker Brothers Life Sciences Capital (GP), LLC Large shareholder
88,657 +1.0%
18.08
US$1,602,892 		88,657 +1.0% 18.08 US$1,602,892
2011-10-03 2011-09-30 B Purchase Baker Brothers Life Sciences Capital (GP), LLC Large shareholder
43,321 +0.5%
18.19
US$788,122 		43,321 +0.5% 18.19 US$788,122
2011-10-03 2011-09-30 B Purchase Baker Biotech Capital (GP), LLC Large shareholder
13,576 +0.7%
18.08
US$245,450 		13,576 +0.7% 18.08 US$245,450
2011-10-03 2011-09-30 B Purchase Baker Biotech Capital (GP), LLC Large shareholder
6,634 +0.4%
18.19
US$120,690 		6,634 +0.4% 18.19 US$120,690
2011-10-03 2011-09-30 B Purchase 14159 capital (GP), LLC Large shareholder
3,367 +1.2%
18.08
US$60,874 		3,367 +1.2% 18.08 US$60,874
2011-10-03 2011-09-30 B Purchase 14159 capital (GP), LLC Large shareholder
1,645 +0.6%
18.19
US$29,927 		1,645 +0.6% 18.19 US$29,927
2011-10-03 2011-09-29 B Purchase Baker Brothers Life Sciences Capital (GP), LLC Large shareholder
159,945 +1.9%
18.00
US$2,878,882 		159,945 +1.9% 18.00 US$2,878,882
2011-10-03 2011-09-29 B Purchase Baker Biotech Capital (GP), LLC Large shareholder
21,117 +1.1%
18.00
US$380,089 		21,117 +1.1% 18.00 US$380,089
2011-10-03 2011-09-29 B Purchase 14159 capital (GP), LLC Large shareholder
6,084 +2.2%
18.00
US$109,507 		6,084 +2.2% 18.00 US$109,507
2011-10-03 2011-09-29 B Purchase Baker Brothers Life Sciences Capital (GP), LLC Large shareholder
89,970 +1.1%
17.97
US$1,616,392 		89,970 +1.1% 17.97 US$1,616,392
2011-10-03 2011-09-29 B Purchase Baker Biotech Capital (GP), LLC Large shareholder
11,878 +0.6%
17.97
US$213,399 		11,878 +0.6% 17.97 US$213,399
2011-10-03 2011-09-29 B Purchase 14159 capital (GP), LLC Large shareholder
3,423 +1.3%
17.97
US$61,497 		3,423 +1.3% 17.97 US$61,497
2011-09-26 2011-09-26 B Purchase Baker Biotech Capital (GP), LLC Large shareholder
4,697 +0.3%
18.13
US$85,155 		4,697 +0.3% 18.13 US$85,155
2011-09-26 2011-09-26 B Purchase Baker Biotech Capital (GP), LLC Large shareholder
22,084 +1.2%
18.13
US$400,295 		22,084 +1.2% 18.13 US$400,295
2011-09-26 2011-09-26 B Purchase 14159 capital (GP), LLC Large shareholder
1,103 +0.4%
18.13
US$19,997 		1,103 +0.4% 18.13 US$19,997
2011-09-26 2011-09-26 B Purchase 14159 capital (GP), LLC Large shareholder
5,184 +1.9%
18.13
US$93,965 		5,184 +1.9% 18.13 US$93,965
2011-09-26 2011-09-26 B Purchase Baker Brothers Life Sciences Capital (GP), LLC Large shareholder
28,000 +0.3%
18.13
US$507,632 		28,000 +0.3% 18.13 US$507,632
2011-09-26 2011-09-26 B Purchase Baker Brothers Life Sciences Capital (GP), LLC Large shareholder
131,641 +1.6%
18.13
US$2,386,125 		131,641 +1.6% 18.13 US$2,386,125
2011-09-26 2011-09-23 B Purchase Baker Biotech Capital (GP), LLC Large shareholder
8,828 +0.5%
17.78
US$156,988 		8,828 +0.5% 17.78 US$156,988
Explore more

More insider trading research around Shire Viropharma Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America